Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype.

× No keyword cloud information.

110 in total

1. Current medical therapy of inflammatory bowel disease.

Authors: Kiron M Das; Sherif A Farag
Journal: World J Gastroenterol Date: 2000-08 Impact factor: 5.742

Review 2. Combination therapy for autoimmune diseases: the rheumatoid arthritis model.

Authors: N Fathy; D E Furst
Journal: Springer Semin Immunopathol Date: 2001

3. Mesalazine is safe for the treatment of IBD.

Authors: G D'Haens; A A van Bodegraven
Journal: Gut Date: 2004-01 Impact factor: 23.059

Review 4. Drug therapy of ulcerative colitis.

Authors: B Crotty; D P Jewell
Journal: Br J Clin Pharmacol Date: 1992-09 Impact factor: 4.335

Review 5. Sulfasalazine. Multiplicity of action.

Authors: T S Gaginella; R E Walsh
Journal: Dig Dis Sci Date: 1992-06 Impact factor: 3.199

6. Is mesalamine safe?

Authors: Kenneth W Schroeder
Journal: Gastroenterol Hepatol (N Y) Date: 2007-11

7. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines.

Authors: R A J Ransford; M J S Langman
Journal: Gut Date: 2002-10 Impact factor: 23.059

8. Sulfasalazine-induced pulmonary disease.

Authors: R H Moseley; K W Barwick; K Dobuler; V A DeLuca
Journal: Dig Dis Sci Date: 1985-09 Impact factor: 3.199

9. Simultaneous analysis of dapsone and monoacetyldapsone employing high performance liquid chromatography: a rapid method for determination of acetylator phenotype.

Authors: K Carr; J A Oates; A S Nies; R L Woosley
Journal: Br J Clin Pharmacol Date: 1978-11 Impact factor: 4.335

10. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide.

Authors: P W Lowry; C L Franklin; A L Weaver; C L Szumlanski; D C Mays; E V Loftus; W J Tremaine; J J Lipsky; R M Weinshilboum; W J Sandborn
Journal: Gut Date: 2001-11 Impact factor: 23.059